<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325090</url>
  </required_header>
  <id_info>
    <org_study_id>I09006 / APTODON</org_study_id>
    <secondary_id>2010-021506-38</secondary_id>
    <nct_id>NCT01325090</nct_id>
  </id_info>
  <brief_title>Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy</brief_title>
  <acronym>APTODON</acronym>
  <official_title>Early Administration of Botulinum Toxin Type A (Botox®) in Neuropathic Pain Due to Thoracoscopy or Thoracotomy: a Randomized, Double Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin type A has been reported to inhibit the release of various pain
      neurotransmitters (SP, CGRP, glutamate) responsible for neurogenic inflammation, a process
      that results from the sensitization of C-fiber nociceptors (peripheral sensitization). This
      action is probably responsible for the analgesic effect of botulinum toxin type A recently
      demonstrated in patients with neuropathic pain of peripheral origin.In those studies,
      patients had been suffering for years. The investigators can hypothesizes that earlier
      administration of Botox in the course of neuropathic pain might prevent central
      sensitization, that is secondary to peripheral sensitization. The investigators can hope to
      increase efficacy of Botulinum toxin type A injections and to prevent chronification of pain.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in average pain intensity as measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS in the last 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Inventory</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain Due to Certain Specified Procedures</condition>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>BOTOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX</intervention_name>
    <description>A syringe of 1 ml contain 25 Allergan units.</description>
    <arm_group_label>BOTOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  daily pain, for 3 months, secondary to thoracoscopy or thoracotomy, of neuropathic
             origin (DN4 questionary)

        Exclusion Criteria:

          -  contraindications for botulinum toxin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danièle RANOUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <name_title>Marie SENGELEN / Directrice de la Recherche et de l'Innovation</name_title>
    <organization>CHU de Limoges</organization>
  </responsible_party>
  <keyword>neuropathic pain due to thoracotomy</keyword>
  <keyword>Neuropathic Pain Due to Thoracoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

